Movement disorders : official journal of the Movement Disorder Society · 2026
Plasma p-tau217 Versus p-tau181 in Parkinson's Disease: Differential Associations with Alzheimer's Disease-Related Neurostructural Changes and Cognitive Function.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Fiorenzato Eleonora, Cauzzo Simone, Musso Giulia, Biundo Roberta, Ceolin Chiara, Cosma Chiara, Fogliano Carmelo Alessandro, Meissner Wassilios G, Misenti Valentina, Moz Stefania, Nasi Maria Laura, Vianello Francesca, Manara Renzo, Montagnana Martina, Sergi Giuseppe, Antonini Angelo, OPA Working Group
Аннотация
BACKGROUND: Plasma phosphorylated-tau at threonine-217 (p-tau217) and threonine-181 (p-tau181) are scalable, minimally invasive biomarkers of Alzheimer's disease (AD) pathology. In Parkinson's disease (PD), AD co-pathology may contribute to its clinical heterogeneity. However, the existing literature has predominantly focused on p-tau181, with comparatively limited investigation of p-tau217.
OBJECTIVE: The aim is to evaluate plasma p-tau217 and p-tau181 as biomarkers of AD co-pathology across the PD cognitive spectrum, relative to a cohort of dementia-free older adults.
METHODS: Plasma p-tau217 and p-tau181 were measured in 70 PD patients and 83 older adults. Associations with cognitive impairment, disease severity (Hoehn-and-Yahr), and neurostructural measures-including global atrophy, hippocampal volume, and a magnetic resonance imaging-based AD signature-were assessed using correlation and dominance analyses.
RESULTS: Both p-tau217 and 181 were higher in PD with cognitive impairment and dementia compared with cognitively normal PD. P-tau217 showed stronger associations than p-tau181 with AD-like neurostructural changes, multidomain cognitive deficits, greater disease severity, and reduced functional independence.
CONCLUSIONS: Plasma p-tau217 and p-tau181 may serve as scalable markers of AD-related processes associated with neurostructural, clinical, and cognitive outcomes in PD. © 2026 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
OBJECTIVE: The aim is to evaluate plasma p-tau217 and p-tau181 as biomarkers of AD co-pathology across the PD cognitive spectrum, relative to a cohort of dementia-free older adults.
METHODS: Plasma p-tau217 and p-tau181 were measured in 70 PD patients and 83 older adults. Associations with cognitive impairment, disease severity (Hoehn-and-Yahr), and neurostructural measures-including global atrophy, hippocampal volume, and a magnetic resonance imaging-based AD signature-were assessed using correlation and dominance analyses.
RESULTS: Both p-tau217 and 181 were higher in PD with cognitive impairment and dementia compared with cognitively normal PD. P-tau217 showed stronger associations than p-tau181 with AD-like neurostructural changes, multidomain cognitive deficits, greater disease severity, and reduced functional independence.
CONCLUSIONS: Plasma p-tau217 and p-tau181 may serve as scalable markers of AD-related processes associated with neurostructural, clinical, and cognitive outcomes in PD. © 2026 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.